Publication Topic

Covington TR, Barton HA, Clewell HJ III. Evaluating pharmacokinetics and pharmacodynamics for noncancer effects from trichloroethylene (TCE). Poster presented at the Society of Toxicology Annual Meeting, Cincinnati, OH, March 1997.

Fraiser LH, Lund LG, Tyndall KH, King ME, Schultz DA, Haws LC. Case Studies in risk assessment for hazardous waste burning cement kilns. Air and Waste Management Association Specialty Conference-Waste Combustion in Boilers and Industrial Furnaces, Kansas City, MO, March 1996.

Ramu K, Perry CS, Ahmed T, Pakenham G, and Kehrer JP. 1996. Studies on the basis for the toxicity of acrolein mercapturates. Toxicol Appl Pharmacol 140(2):487-498; doi: 10.1006/taap.1996.0245.

Sauers L and Perry C. 1996. Regulatory affairs – A growing opportunity for toxicologists. SOT Communiqué, May/June 1996.

McCoy JT, Haws LC, Carlisle LC, Wiersema JM, Carmichael D, Mgebroff S. Soil sampling and analysis for PCDDs/PCDFs downwind of combustion sources in six Texas communities. Society of Environmental Toxicology and Chemistry Annual Meeting, 1996.

Choksi NY, Kodavanti PRS, Tilson H, Booth RG. 1996. Effects of polychlorinated biphenyls on brain tyrosine hydroxylase activity in rats. Fundam Appl Toxicol 39(1):76–80; doi: 10.1006/faat.1997.2351.

Hochberg F, Miller G, Valenzuela R, McNelis S, Crump KS, Covington T, Valdivia G, Hochberg B, Trustman JW. 1996. Late motor deficits of Chilean manganese miners: A blinded control study. Neurology 47:788–795.

Allen BC, Covington TR, Clewell HJ III. 1996. Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. Toxicology 111:289–303.

Choksi NY, Hussain A, Booth RG. 1996. 2-Phenylaminoadenosine stimulates adenylyl cyclase activity and dopamine biosynthesis through an A2 receptor mediated mechanism. Brain Res 761(1):151–155; doi: 10.1016/s0006-8993(97)00445-9.

Choksi NY, Wyrick SD, Booth RG. Modulation of brain dopamine synthesis in vivo by a putative σ 3 agonist via a G-protein coupled receptor mechanism. Poster presented at Society for Neuroscience Annual Meeting, 1996

Lea IA, Richardson RT, Widgren EE, O’Rand MG. 1996. Cloning and sequencing of cDNAs encoding the human sperm protein, Sp17. Biochim Biophys Acta 1307(3):263–266; doi: 10.1016/0167-4781(96)00077-2.

Covington TR, Clewell HJ III, Gearhart JM, Andersen ME. Developing physiologically-based pharmacokinetic (PB-PK) models for manganese and iron. Poster presented at the Society of Toxicology Annual Meeting, Anaheim, CA, March 1996.

Fraiser LH, Lund LG, Hueske KL, Haws LC. Indirect risk assessment: Case studies of hazardous waste combustors. Society of Toxicology 34th Annual Meeting, Baltimore, MD, March 1995.

Huber KM, Mauk MD, Thompson CM, Kelly PT. 1995. A critical period of protein kinase activity after tetanic stimulation is required for the induction of long-term potentiation. Learn Memor 2:81–100; doi: 10.1101/lm.2.2.81.

Choksi NY, Waller CL, Booth RG. Neurotoxic and neuroprotective effects of polychlorinated biphenyls and adenosine compounds in rat brain. Presented at Society for Neuroscience Annual Meeting, San Diego, CA, November 1995.

Perry CS, Liu XL, Lund LG, Kehrer JP. 1995. Differential toxicities of cyclophosphamide and its glutathione metabolites to A549 cells. Toxicol in Vitro 9(1):21-26; doi: 10.1016/0887-2333(94)00187-Y.

Norton JN, Rylander LA, Richards JL. 1995. In vitro oral mucosa irritation testing with human cell cultures. Toxicol In Vitro 9(1):67–74; 10.1016/0887-2333(94)00189-2.

Prioleau C, Montague DM, Choksi NY, Southerland SB, Lawler CP, Mailman RB. Unusual neurochemical properties of the novel antipsychotic OPC-14597 in rat striatum. Poster presented at Society for Neuroscience Annual Meeting, 1995.

Covington TR, Gearhart JM, Clewell HJ. A physiologically based pharmacokinetic (PBPK) model for 133Xe and 222Rn in the human. Poster presented at the Society of Toxicology Annual Meeting, Baltimore, MD, March 1995.

Gargas M, Norton R, Harris MA, Paustenbach D, Finley B. 1994. Urinary excretion of chromium following ingestion of chromite ore processing residue in humans: Implications for biomonitoring. Risk Anal 14(6):1019-1024; doi: 10.1111/j.1539-6924.1994.tb00071.x.